ZUO LI YAO YE(300181)2020-04-26 16:00Financial Performance - Total operating revenue for Q1 2020 was ¥193,188,846.44, a decrease of 5.02% compared to ¥203,396,016.80 in the same period last year[9] - Net profit attributable to shareholders was ¥10,922,165.26, representing a slight increase of 0.92% from ¥10,823,109.10 year-on-year[9] - Basic and diluted earnings per share were both ¥0.0179, an increase of 0.56% from ¥0.0178 in the same period last year[9] - The company's operating income for the reporting period was 193.19 million yuan, a decrease of 10.21 million yuan, or 5.02%, compared to the same period last year[24] - The net profit attributable to shareholders for the reporting period was 10.92 million yuan, an increase of 0.99 million yuan, or 0.92%, year-on-year[24] - Net profit for Q1 2020 was CNY 11,225,886.49, an increase of 2.5% from CNY 10,947,966.08 in Q1 2019[55] - The total comprehensive income for the first quarter was CNY 8,045,341.34, compared to CNY 6,998,869.91 in the previous year, reflecting a growth of approximately 15%[59] Cash Flow - Net cash flow from operating activities was -¥64,940.40, showing a significant improvement of 99.67% compared to -¥19,562,341.27 in the previous year[9] - The cash outflow from operating activities was 0.65 million yuan, a decrease of 19.50 million yuan, or 99.67%, year-on-year[23] - Cash flow from operating activities showed a net outflow of CNY -64,940.40, a significant improvement from CNY -19,562,341.27 in the previous year[62] - Operating cash inflow for the current period reached 80,592,679.01 in the previous period, reflecting a growth of approximately 53.4%[64] - Net cash flow from operating activities improved to -51,627,918.25, indicating a reduction in cash outflow by about 43%[64] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,082,435,441.34, up 1.55% from ¥2,050,645,692.02 at the end of the previous year[9] - Total liabilities were CNY 663,421,441.20, compared to CNY 642,857,578.37, reflecting an increase of about 3%[49] - The company's equity attributable to shareholders reached CNY 1,321,276,335.45, up from CNY 1,310,354,170.19, indicating a growth of approximately 0.8%[50] - Current assets totaled CNY 715,812,510.75, up from CNY 690,910,086.08, indicating an increase of about 3.5%[46] - The ending balance of cash and cash equivalents was 137,796,774.39, reflecting a decrease of approximately 28.5%[66] Investments and R&D - R&D expenses for the reporting period amounted to 6.90 million yuan, an increase of 1.91 million yuan, or 38.36%, compared to the same period last year[23] - R&D expenses increased to CNY 6,898,374.60 in Q1 2020, up from CNY 4,985,706.28 in the same period last year, indicating a focus on innovation[54] - The company has invested CNY 296.01 million in the project to build a 400-ton annual production line for mushroom powder, achieving 75.84% of the planned investment[36] Operational Challenges - The COVID-19 pandemic has delayed the company's resumption of work after the Spring Festival, impacting production, R&D, and logistics, with a decrease in hospital visits affecting drug demand[8] - The company plans to closely monitor the pandemic's development and adjust operations accordingly to mitigate financial impacts[8] - The company plans to closely monitor industry policy changes and implement measures to mitigate risks associated with industry regulations and price reductions[26] - The company is actively investing in the health industry to seize market opportunities, but faces risks from changes in macro policies, market conditions, and technology that could affect project profitability[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 43,828[15] - There are no violations regarding external guarantees or non-operational fund occupation by controlling shareholders during the reporting period[42]